Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Recommendation of “Buy” from Analysts

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have been assigned an average rating of “Buy” from the eleven analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $21.10.

A number of research analysts recently issued reports on TRVI shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Wednesday, January 21st. Morgan Stanley lifted their price target on shares of Trevi Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research note on Friday, November 14th. Oppenheimer increased their price objective on shares of Trevi Therapeutics from $23.00 to $24.00 and gave the stock an “outperform” rating in a research report on Friday, November 14th. B. Riley Financial upgraded Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, November 17th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of Trevi Therapeutics in a research note on Friday, January 9th.

Institutional Trading of Trevi Therapeutics

Several hedge funds have recently bought and sold shares of TRVI. Vivo Capital LLC boosted its holdings in Trevi Therapeutics by 28.7% during the 2nd quarter. Vivo Capital LLC now owns 4,487,903 shares of the company’s stock worth $24,549,000 after acquiring an additional 1,000,000 shares during the last quarter. Prudential Financial Inc. bought a new position in shares of Trevi Therapeutics during the second quarter valued at about $1,238,000. Flputnam Investment Management Co. boosted its holdings in Trevi Therapeutics by 1,105.4% during the third quarter. Flputnam Investment Management Co. now owns 1,048,102 shares of the company’s stock worth $9,590,000 after purchasing an additional 961,150 shares during the last quarter. Jefferies Financial Group Inc. bought a new stake in Trevi Therapeutics in the 2nd quarter worth about $301,000. Finally, AXQ Capital LP purchased a new stake in Trevi Therapeutics in the 2nd quarter valued at about $227,000. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Trading Down 1.0%

TRVI stock opened at $10.94 on Friday. The firm has a market cap of $1.40 billion, a PE ratio of -29.57 and a beta of 0.94. The stock has a 50-day moving average price of $11.72 and a 200-day moving average price of $10.24. Trevi Therapeutics has a 1-year low of $3.93 and a 1-year high of $14.39.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Thursday, November 13th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.02. On average, analysts forecast that Trevi Therapeutics will post -0.49 earnings per share for the current year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.